{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T01:14:17Z","timestamp":1755998057785,"version":"3.41.0"},"reference-count":20,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T00:00:00Z","timestamp":1534896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Kitasato University Medical School \u201cShogaku-Kifu\u201d unrestricted research support","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Nephrology"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Patients with diabetic nephropathy develop nephrotic syndrome and may show limited response to conventional therapy. They often require earlier initiation of renal replacement therapy because they become refractory to diuretics, and experience excessive fluid retention. We aimed to investigate the efficacy of tolvaptan, an oral arginine vasopressin type 2 receptor antagonist, in a case series of 14 severe diabetic renal failure patients who were severely refractory to maximal doses of furosemide and had excessive fluid retention despite preserved cardiac function and residual renal function. All 14 patients experienced immediate and sustained water diuretic effects, resulting in alleviation of congestive heart failure. None required initiation of renal replacement therapy. Tolvaptan promptly increased urine volume and free water clearance, reversed progressive fluid retention, and alleviated congestive heart failure. Thus, tolvaptan could serve as a potential adjunct therapy for severe diabetic renal failure patients with excessive fluid retention and congestive heart failure.<\/jats:p>","DOI":"10.1111\/nep.13390","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T17:16:08Z","timestamp":1523985368000},"page":"883-886","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide"],"prefix":"10.1111","volume":"23","author":[{"given":"Tesshu","family":"Takada","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism Kitasato University School of Medicine Sagamihara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuguto","family":"Masaki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism Kitasato University School of Medicine Sagamihara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Hoshiyama","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism Kitasato University School of Medicine Sagamihara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Toki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism Kitasato University School of Medicine Sagamihara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Kamata","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism Kitasato University School of Medicine Sagamihara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5704-1378","authenticated-orcid":false,"given":"Masayoshi","family":"Shichiri","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism Kitasato University School of Medicine Sagamihara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,8,22]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep26380"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.46.1.79"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.27443"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02374506"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000047397"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2003.08.012"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1990.332"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.12.072"},{"key":"e_1_2_6_10_1","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","article-title":"OPC\u201041061, a highly potent human vasopressin V2\u2010receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats","volume":"287","author":"Yamamura Y","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00195.2005"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.02.027"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-66-0093"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000070422.41439.04"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.12.1332"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.16.1963"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-015-0775-9"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.14-190"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0194-6"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-12-0971"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.350"}],"container-title":["Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fnep.13390","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nep.13390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T18:53:46Z","timestamp":1751568826000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/nep.13390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,22]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1111\/nep.13390"],"URL":"https:\/\/doi.org\/10.1111\/nep.13390","archive":["Portico"],"relation":{},"ISSN":["1320-5358","1440-1797"],"issn-type":[{"type":"print","value":"1320-5358"},{"type":"electronic","value":"1440-1797"}],"subject":[],"published":{"date-parts":[[2018,8,22]]},"assertion":[{"value":"2018-04-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}